A 76-year-old woman presents with newly diagnosed non-valvular atrial fibrillation. She has hypertension and type 2 diabetes but no prior stroke, heart failure or vascular disease. Her CHA₂DS₂-VASc score is 4. Renal function is normal. According to Canadian atrial fibrillation guidance, which is the most appropriate antithrombotic strategy?